Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03452774 · ClinicalTrials.gov registry record

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

A clinical trial of Cancer and Cancer Metastatic, sponsored by Massive Bio.

Recruiting
Registry status
50,000
Enrollment target
20
Study locations

NCT03452774 is a study of Cancer and Cancer Metastatic that is actively recruiting participants, run by Massive Bio. The registered enrollment target is 50,000 participants, above the 3,410-participant average among 615 other Cancer trials with a reported enrollment target (1366% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03452774, a study of Cancer and Cancer Metastatic, is actively recruiting participants, sponsored by Massive Bio.

RECRUITING
Registry status
50,000 participants
Enrollment target
20
Study locations

Study Summary

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Conditions Studied

Cancer Cancer Metastatic Cancer of Pancreas Cancer of Esophagus Cancer of Liver Cancer of Rectum Cancer of Cervix Cancer of Stomach Cancer Liver Cancer of Kidney

Interventions

  • OTHER Clinical Trial Matching

Study Locations (20)

California

  • Massive Bio SYNERGY-AI site - Duarte
  • Massive Bio SYNERGY-AI site - Irvine
  • Massive Bio SYNERGY-AI site - La Jolla
  • Massive Bio SYNERGY-AI site - Orange
  • Massive Bio SYNERGY-AI site - San Francisco
  • Massive Bio SYNERGY-AI site - Stanford

Colorado

  • Massive Bio SYNERGY-AI site - Aurora
  • Massive Bio SYNERGY-AI site - Denver
  • Massive Bio SYNERGY-AI site - Littleton

Florida

  • Massive Bio SYNERGY-AI site - Jacksonville
  • Massive Bio SYNERGY-AI site - Miami
  • Massive Bio SYNERGY-AI site - Tampa

Alabama

  • Massive Bio SYNERGY-AI site - Birmingham
  • Massive Bio SYNERGY-AI site - Mobile

Connecticut

  • Massive Bio SYNERGY-AI site - Hartford
  • Massive Bio SYNERGY-AI site - Norwalk

Arizona

  • Massive Bio SYNERGY-AI site - Scottsdale

Arkansas

  • Massive Bio SYNERGY-AI site - Little Rock

Delaware

  • Massive Bio SYNERGY-AI site - Newark

Trial Details

FieldValue
Enrollment Target 50,000 participants
Start Date 2018-01-01
Est. Completion 2040-06

Sponsor

Massive Bio

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03452774

The ClinicalTrials.gov registry entry for NCT03452774 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,410-participant average among 615 other Cancer trials with a reported enrollment target (1366% higher). The listed sponsor is Massive Bio, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Clinical Trial Matching is the first listed.

NCT03452774 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT03452774 about?

NCT03452774 is a clinical study titled "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry". International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical ...

What is the current status of trial NCT03452774?

This trial is currently recruiting. The enrollment target is 50,000 participants. The study started on 2018-01-01. Estimated completion is 2040-06.

What conditions does trial NCT03452774 study?

This clinical trial studies the following conditions: Cancer, Cancer Metastatic, Cancer of Pancreas, Cancer of Esophagus, Cancer of Liver.

What interventions are being tested in trial NCT03452774?

The interventions under investigation include: Clinical Trial Matching (OTHER).

Who is sponsoring clinical trial NCT03452774?

This trial is sponsored by Massive Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03452774 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Cancer Metastatic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.